Denver, Colorado - Midday trading is being shaped by a powerful mix of biotech momentum, breakthrough materials science, and strategic buyouts, as investors rotate toward companies delivering tangible catalysts.
Spider Silk Headlines Power Materials Story
Shares of Kraig Biocraft Laboratories (OTCQB:KBLB) are pressing toward 52-week highs after the company’s recombinant spider silk platform landed on the cover of National Geographic’s March 2026 issue.
The feature spotlighted Kraig’s genetically enhanced silkworm technology, which produces spider silk fibers as part of the insect’s natural biological process. Demonstrations highlighted in the article included towing a car and suspending a person using a lightweight loop of spider silk thread, underscoring the material’s strength-to-weight profile.
The timing aligns with a key operational inflection point. Kraig is preparing to deploy approximately one million proprietary spider silk silkworm eggs across three production facilities in Vietnam, targeting output of up to 10 metric tons of cocoons per month beginning in March. If sustained output materializes, KBLB could become only the second company in history to achieve commercial-scale production from a transgenic animal platform, a milestone historically associated with ATryn, later incorporated into Sanofi (NASDAQ:SNY) following its acquisition of Genzyme.
Scientific validation of the platform was previously published in the Proceedings of the National Academy of Sciences, confirming fibers tougher than conventional silk and comparable to native spider dragline silk. While several startups have attempted to replicate the spider silk thesis over the past decade, many raising significant capital before pivoting, Kraig’s vertically integrated biological production model is now being tested at industrial scale.
Adding historical perspective, National Geographic noted that in the 1930s, inspired by silk architecture, DuPont (NYSE:DD) developed nylon. DuPont later pursued synthetic spider silk production in bacteria without achieving commercial fiber output.
With production ramping and prior disclosures pointing to global brand engagements in luxury fashion, performance sportswear, and athletic equipment, the market is watching closely for confirmation of initial deliveries.
Please click here to read the full Kraig Labs analyst report on 247marketnews.com.
Interested persons can order a copy of the magazine from National Geographic at https://ngsingleissues.nationalgeographic.com/natgeo-march-2026.
You can purchase a digital copy of the article directly from National Geographic at https://www.nationalgeographic.com/science/article/spider-silk-silkworm-genetic-engineering
** Photography by Mark Thiessen, NGM Staff, Image Copyright: National Geographic Magazine
ImmunityBio Breaks Out on Revenue Surge and Global Expansion
Biotech strength continues to build around ImmunityBio (NASDAQ:IBRX), which hit a new 52-week high of $11 after reporting approximately $113 million in full-year 2025 net product revenue for ANKTIVA, representing roughly 700% year-over-year growth.
Unit sales volume increased approximately 750%, with fourth-quarter net product revenue reaching $38.3 million, up 431% year-over-year.
Regulatory expansion has been equally aggressive. ANKTIVA in combination with BCG is now authorized across 33 countries spanning the United States, United Kingdom, European Union, and Saudi Arabia for BCG-unresponsive non-muscle invasive bladder cancer. In January 2026, Saudi Arabia granted conditional accelerated approval for ANKTIVA in combination with checkpoint inhibitors for metastatic non-small cell lung cancer, marking the first approval beyond bladder cancer.
Founder Dr. Patrick Soon-Shiong described the lung cancer authorization as “a defining moment,” emphasizing the company’s pursuit of accelerated approvals in additional jurisdictions and engagement with the U.S. FDA regarding a regulatory pathway.
Financially, ImmunityBio ended the year with $242.8 million in cash and marketable securities. While R&D spending rose to support expanded clinical programs, net loss narrowed year-over-year as revenue scaled and SG&A costs declined.
The company’s 3-year strategy positions ANKTIVA as a backbone immunotherapy platform across multiple tumor types, supported by patent protection extending beyond 2035.
Tandem Diabetes Delivers Billion-Dollar Milestone
Medical device momentum is also lifting Tandem Diabetes Care (NASDAQ:TNDM), which continues to rally following strong Q4 and full-year results.
Tandem surpassed $1.015 billion in worldwide sales for 2025, achieved record quarterly gross margins of 58%, and delivered positive operating income in Q4. Pump shipments exceeded 126,000 globally for the year.
CEO John Sheridan called 2025 “a defining year,” highlighting operational modernization and innovation, including expanded pump integrations and new mobile control capabilities. Investors are now digesting 2026 guidance as the company pushes further into multi-channel distribution and expanded FDA indications.
Healthcare M&A: Enhabit Goes Private in $1.1B Deal
In the home health space, Enhabit (NYSE:EHAB) agreed to be acquired by Kinderhook Industries in an all-cash transaction valued at approximately $1.1 billion.
Stockholders will receive $13.80 per share in cash, representing a 24.4% premium to the prior close and a 33.8% premium to the 60-day VWAP. Upon completion, Enhabit will delist from the NYSE and operate as a private company.
Chairman Jeffrey Bolton said the board concluded the transaction “maximizes value for our stockholders,” while CEO Barb Jacobsmeyer emphasized the opportunity to invest in long-term growth outside the pressures of public markets.
Robotics and Retail Automation Advance
Meanwhile, VenHub Global (NASDAQ:VHUB) announced next-generation robotic upgrades introducing self-diagnostic capabilities and predictive maintenance across its autonomous Smart Store network. The enhancements are designed to improve uptime and support 24/7 retail automation as deployment accelerates.
Small-Cap Watch
Signing Day Sports (NYSE:SGN) continues its January rally, clearing technical resistance near $0.60 as traders eye the next pivot level at around 95-cents.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) is a biotechnology company focused on the development and commercialization of spider silk-based fiber technologies. Through its proprietary silkworm-based genetic engineering platform, Kraig Labs produces high-performance, cost-effective, and scalable spider silk materials for use in defense, performance apparel, technical textiles, and medical applications.
For more information about Kraig Labs’ spider silk technology and partnership opportunities, visit www.kraiglabs.com
About 24/7 Market News
In today's fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247marketnews.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24/7 is a third-party media provider that owns KBLB shares, which are on deposit and may be sold at the editor’s discretion, and has been compensated for providing ongoing KBLB market outreach and other services.. This press release may include technical analysis and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions.
For further information, please visit 247marketnews.com or https://go.247marketnews.com/kblb-disclosure/
CONTACT:
24/7 Market News
Editor@247marketnews.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.
